Results 131 to 140 of about 118,448 (336)

Speech Differences between Multiple System Atrophy and Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Delineation of Parkinson's disease (PD) from multiple system atrophy (MSA) can be challenging in early disease stages. Speech characteristics have been studied as digital biomarkers in PD and ataxias. Currently, data on speech in MSA is limited.
Tom Hähnel, Anna Nemitz, Katja Schön, Luise Berger, Annemarie Vogel, Doreen Gruber, Nils Schnalke, Stefan Bräuer, Björn H. Falkenburger, Florin Gandor   +9 more
wiley   +1 more source

Investigating Dopamine Replacement–Associated Fluctuations in Cognition and Mood in Cognitively Unimpaired Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor fluctuations, characterized by variability in mood and cognition, are prevalent in advanced Parkinson's disease (PD), but less is known about these fluctuations in early PD. Objective The objective was to characterize fluctuations in cognition and mood in early PD without cognitive impairment.
Abhimanyu Mahajan, Christopher B. Morrow, Joseph Seemiller, Kelly A. Mills, Gregory M. Pontone   +4 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN‐Open‐Label Study

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA (DAXI), a novel botulinum neurotoxin (BoNT) formulation, was shown to be safe, effective, and long‐lasting in the treatment of cervical dystonia (CD) over one treatment cycle in the phase 3, randomized, placebo‐controlled ASPEN‐1 trial.
Peter McAllister, Atul T. Patel, Marta Banach, Aaron Ellenbogen, Jaroslaw Slawek, Sebastian Paus, Hyder A. Jinnah, Virgilio Evidente, Todd M. Gross, Rashid Kazerooni, Conor J. Gallagher, David A. Hollander   +11 more
wiley   +1 more source

Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review. [PDF]

Cureus, 2023
Bazuhair T, Aleid B, Almalki M.
europepmc   +1 more source

Dopaminergic Regulation of Progesterone Receptors: Brain D5 Dopamine Receptors Mediate Induction of Lordosis by D1-Like Agonists in Rats [PDF]

, 1996
Ede Marie Apostolakis, János Garai, Charles A. Fox, C. Smith, Stanley J. Watson, James H. Clark, Bert W. O’Malley   +6 more
openalex   +1 more source

Tics and Parkinson's Disease: Clinical and Pathophysiological Insights from a Rare Syndromic Association

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The coexistence of tics with Parkinson's disease (PD) is rare, as they often emerge at different ages, follow different trajectories and involve contrasting pathophysiological mechanisms related to dopamine availability and function in the brain. Cases We present 10 individuals with primary tic disorders who later developed PD.
Tarig Abkur, Alexandra Boogers, Talyta Grippe, David A. Isaacs, Irene A. Malaty, Renato P. Munhoz, Kailash P. Bhatia, Lauren A. Hart, Alfonso Fasano, Suneil Kalia, Anthony E. Lang, Christos Ganos   +11 more
wiley   +1 more source

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist. [PDF]

Case Rep Dermatol, 2022
Talty R, Micevic G, Wang A, Ko CJ, Damsky W.   +4 more
europepmc   +1 more source

The agonist activities of the putative antipsychotic agents, L‐745,870 and U‐101958 in HEK293 cells expressing the human dopamine D_4.4 receptor [PDF]

, 1998
Lucien Gazi, Ionel Bobirnac, M Danzeisen, E. Schüpbach, Anne T. Bruinvels, Sabine Geisse, Bernd Sommer, Daniël Hoyer, Mark D. Tricklebank, Philippe Schoeffter   +9 more
openalex   +1 more source

Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine

, 1988
E. Ciccarelli, R. Touzel, Michael Besser, A. Grossman   +3 more
openalex   +1 more source

Ropinirole: A dopamine agonist for the treatment of Parkinson’s disease [PDF]

, 1999
Mary D. Kuzel
openalex   +1 more source